Clene Unveils Biomarker Data Supporting ALS NDA, Targets Q4 Filing
CLNN sits 51% above its 52-week low of $3.5.
Summary
Clene Inc. announced positive biomarker analyses supporting an accelerated approval NDA for its ALS drug CNM-Au8, with submission planned for early Q4 2026. The data show a survival benefit concentrated in patients whose NfL biomarker responded to treatment.
Key Events · Product Development and Regulatory · CLNN
-
Biomarker Data Supports ALS NDA
New analyses from the HEALEY and RESCUE-ALS trials reveal that CNM-Au8-treated patients whose NfL declined or stabilized had a 38% lower risk of death versus controls (HR 0.621, p=0.037) and significant functional benefits on CAFS.
-
NDA Submission Planned for Early Q4 2026
Following FDA feedback from a March 2026 Type C meeting, Clene will submit an NDA for accelerated approval of CNM-Au8 for ALS, using NfL as a surrogate endpoint.
-
Phase 3 Confirmatory Trial Designed
RESTORE-ALS, a 690-patient global trial, will prospectively evaluate the NfL biomarker relationship, with initiation planned for Q2 2027.
-
Cash Runway Extends Only to Q4 2026
With $12.9M in cash as of March 31, 2026, Clene has sufficient funds only into Q4 2026, making the NDA submission and potential approval critical for survival.
Analysis · CLNN · Life Sciences
Clene disclosed new biomarker analyses from its two Phase 2 ALS trials showing that CNM-Au8-treated patients whose neurofilament light chain (NfL) levels declined or stabilized lived significantly longer and had better functional outcomes than controls. The company plans to submit a New Drug Application for accelerated approval in early Q4 2026, using NfL as a surrogate endpoint. This is a major regulatory catalyst for a micro-cap biotech with a cash runway only into Q4 2026 — the NDA filing and FDA review will determine the company's future.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.6% of the 972 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLNN was trading at $5.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.5M. The 52-week trading range was $3.50 to $13.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.